Piper Sandler analyst David Westenberg raised the firm’s price target on Illumina (ILMN) to $190 from $185 following quarterly results. The ...

Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to ...

Illumina, Inc. (NASDAQ:ILMN – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Wednesday after Morgan Stanley lowered their price target on the stock from $150.00 to ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

Baird lowered the firm’s price target on Illumina (ILMN) to $127 from $144 and keeps a Neutral rating on the shares. The firm updated its model ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Shares of genomics company Illumina (NASDAQ:ILMN) fell 8.6% in the morning session after the company reported fourth-quarter ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...